-The Hindu Tuberculosis (TB) has remained a major infectious disease in developing and poor countries despite all efforts from health agencies to manage and control it. In fact, even an easy and effective way to diagnose the disease has remained a challenge. Emergence of drug resistant strains has made its management more complex. The steps It makes the situation in countries like India, with the highest TB burden in the world, even more...
More »SEARCH RESULT
Total Matching Records found : 86
Maharahstra, TN account for 36% of sub-standard drugs -Kounteya Sinha
-The Times of India Almost one in three drugs (36%) found "not of standard quality" from across India last year were from Maharashtra (23%) and Tamil Nadu (13%) alone. Around 9.2% of the rest of the sub-standard quality drugs were from Kerala, Gujarat (8.5%), Karnataka (7.2%), Uttar Pradesh (6.9%), Jammu & Kashmir (6.08%) and Rajasthan (5.8%). Union health minister Ghulam Nabi Azad said on Tuesday that of the 48, 082 drug samples tested...
More »Lack of compensation norms for clinical trials results in exploitation of poor patients-Khomba Singh
-The Economic Times Drug companies paid as little as 50,000 as compensation to families of volunteers who died during clinical trials for new medicines last year, leading to sharp criticism about the paltry sums being handed out and growing clamour among health groups for more stringent guidelines on new drug trials. According to government data accessed by a healthcare activist through an RTI query, Germany's Fresenius Kabi paid 50,000 each to the...
More »CDSCO drafting new norms for financial compensation-Mahim Pratap Singh
-The Hindu In the year 2011, 438 people died due to Serious Adverse Events (SAEs) during medicine trials in India, but pharmaceutical companies provided financial compensation in only 16 such cases. The total amount paid in compensation in all the 16 cases adds up to Rs. 34.88 lakh, with the highest amount being Rs. 5 lakh, and the lowest being Rs. 50,000. This makes 2011 only the second year, for which data are...
More »Dogged with corruption, drug regulation is in poor health and ineffective-Khomba Singh
-The Economic Times It's not just the drug regulator, where a parliamentary panel has alleged corruption, failing in its job. Drug regulation across entities that dot this broad landscape is in poor health and ineffective. In May, when a Parliamentary panel, during a routine examination of healthcare regulatory bodies, alleged corruption in the approval of new drugs, it was merely pointing out one symptom. Such symptoms pervade the entire drug regulation landscape,...
More »
